靶向 Syk：脾酪氨酸激酶作为治疗靶点。
Getting Syk: spleen tyrosine kinase as a therapeutic target.
机构信息
Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, Hansen Life Sciences Research Building, 210 South University Street, West Lafayette, IN 47907, USA.
出版信息
Trends Pharmacol Sci. 2014 Aug;35(8):414-22. doi: 10.1016/j.tips.2014.05.007. Epub 2014 Jun 26.
Abstract
Spleen tyrosine kinase (Syk) is a cytoplasmic protein tyrosine kinase well known for its ability to couple immune cell receptors to intracellular signaling pathways that regulate cellular responses to extracellular antigens and antigen-immunoglobulin (Ig) complexes of particular importance to the initiation of inflammatory responses. Thus, Syk is an attractive target for therapeutic kinase inhibitors designed to ameliorate the symptoms and consequences of acute and chronic inflammation. Its more recently recognized role as a promoter of cell survival in numerous cancer cell types ranging from leukemia to retinoblastoma has attracted considerable interest as a target for a new generation of anticancer drugs. This review discusses the biological processes in which Syk participates that have made this kinase such a compelling drug target.
摘要
脾酪氨酸激酶（Syk）是一种细胞质蛋白酪氨酸激酶，以其能够将免疫细胞受体与细胞内信号通路偶联的能力而闻名，这些信号通路调节细胞对外源抗原和抗原-免疫球蛋白（Ig）复合物的反应，这对于启动炎症反应尤为重要。因此，Syk 是治疗性激酶抑制剂的一个有吸引力的靶点，旨在改善急性和慢性炎症的症状和后果。其最近被认为在从白血病到视网膜母细胞瘤的多种癌细胞类型中作为促进细胞存活的促进因子，这使其成为新一代抗癌药物的一个有吸引力的靶点。本文综述了 Syk 参与的生物学过程，这些过程使这种激酶成为一个引人注目的药物靶点。
相似文献
1
Getting Syk: spleen tyrosine kinase as a therapeutic target.靶向 Syk：脾酪氨酸激酶作为治疗靶点。
Trends Pharmacol Sci. 2014 Aug;35(8):414-22. doi: 10.1016/j.tips.2014.05.007. Epub 2014 Jun 26.
2
Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.脾酪氨酸激酶（Syk）抑制剂福他替尼可减轻博来霉素诱导的硬皮病小鼠模型中的组织损伤和纤维化。
Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S15-22. Epub 2015 Jul 6.
3
[Involvement of Syk in pathology of systemic autoimmune disease].[脾酪氨酸激酶在系统性自身免疫性疾病病理学中的作用]
Nihon Rinsho Meneki Gakkai Kaishi. 2012;35(1):56-61. doi: 10.2177/jsci.35.56.
4
Spleen tyrosine kinases: biology, therapeutic targets and drugs.脾脏酪氨酸激酶：生物学、治疗靶点和药物。
Drug Discov Today. 2010 Jul;15(13-14):517-30. doi: 10.1016/j.drudis.2010.05.001. Epub 2010 May 27.
5
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.脾脏酪氨酸激酶作为治疗白血病和淋巴瘤的分子靶标。
Expert Rev Anticancer Ther. 2010 Sep;10(9):1407-18. doi: 10.1586/era.10.112.
6
Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.特异性抑制脾酪氨酸激酶可抑制类风湿关节炎动物模型中的白细胞免疫功能和炎症。
J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. doi: 10.1124/jpet.111.188441. Epub 2011 Oct 31.
7
Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.脾酪氨酸激酶抑制剂：2010-2013 年专利文献综述。
Expert Opin Ther Pat. 2014 May;24(5):573-95. doi: 10.1517/13543776.2014.890184. Epub 2014 Feb 20.
8
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.新型口服生物可利用小分子抑制剂 RO9021 选择性抑制脾酪氨酸激酶 (SYK)，可影响各种固有和适应性免疫反应：SYK 抑制剂在自身免疫性疾病治疗中的应用。
Arthritis Res Ther. 2013 Oct 4;15(5):R146. doi: 10.1186/ar4329.
9
Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.炎症和免疫介导性疾病中开关激酶“脾酪氨酸激酶”抑制剂：综述。
Eur J Med Chem. 2013 Sep;67:434-46. doi: 10.1016/j.ejmech.2013.04.070. Epub 2013 Jul 12.
10
Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.脾酪氨酸激酶在慢性淋巴细胞白血病发病机制中的作用
Leuk Lymphoma. 2014 Dec;55(12):2699-705. doi: 10.3109/10428194.2014.891026. Epub 2014 Mar 18.
引用本文的文献
1
Shared Genes and Pathways in Ulcerative Colitis and Ankylosing Spondylitis: Functional Validation and Implications for Diagnosis.溃疡性结肠炎和强直性脊柱炎中的共享基因与通路：功能验证及对诊断的意义
J Inflamm Res. 2025 Feb 4;18:1657-1678. doi: 10.2147/JIR.S497201. eCollection 2025.
2
Exploration of the Key Pathways and Genes Involved in Osteoarthritis Genesis: Evidence from Multiple Platforms and Real-World Validation.骨关节炎发病机制中关键通路和基因的探索：来自多个平台的证据及真实世界验证
J Inflamm Res. 2024 Dec 4;17:10223-10237. doi: 10.2147/JIR.S488935. eCollection 2024.
3
Spleen tyrosine kinase inhibition mitigates radiation-induced lung injury through anti-inflammatory effects and downregulation of p38 MAPK and p53.脾酪氨酸激酶抑制通过抗炎作用以及下调p38丝裂原活化蛋白激酶和p53减轻辐射诱导的肺损伤。
Front Oncol. 2024 Nov 7;14:1406759. doi: 10.3389/fonc.2024.1406759. eCollection 2024.
4
Gain-of-Function Variant in Spleen Tyrosine Kinase Regulates Macrophage Migration and Functions to Promote Intestinal Inflammation.脾酪氨酸激酶功能获得性变异调节巨噬细胞迁移并促进肠道炎症
J Inflamm Res. 2024 Nov 12;17:8713-8726. doi: 10.2147/JIR.S488901. eCollection 2024.
5
New insights into SYK targeting in solid tumors.在实体瘤中针对 SYK 的新见解。
Trends Pharmacol Sci. 2024 Oct;45(10):904-918. doi: 10.1016/j.tips.2024.08.006. Epub 2024 Sep 24.
6
Protein-Sequence-Based Search of Nonreceptor ITAM-Like Regions to Identify Cytosolic Syk-Recruiting Proteins.基于蛋白质序列的非受体 ITAM 样区域搜索，以鉴定胞质 Syk 募集蛋白。
J Phys Chem B. 2024 Oct 10;128(40):9724-9733. doi: 10.1021/acs.jpcb.4c05185. Epub 2024 Sep 25.
7
Development of a time-resolved fluorescence resonance energy transfer ultra-high throughput screening assay targeting SYK and FCER1G interaction.开发一种针对 SYK 和 FCER1G 相互作用的时间分辨荧光共振能量转移超高通量筛选测定法。
SLAS Discov. 2024 Sep;29(6):100177. doi: 10.1016/j.slasd.2024.100177. Epub 2024 Aug 21.
8
The dualistic role of Lyn tyrosine kinase in immune cell signaling: implications for systemic lupus erythematosus.Lyn 酪氨酸激酶在免疫细胞信号转导中的双重作用：对系统性红斑狼疮的影响。
Front Immunol. 2024 Jun 28;15:1395427. doi: 10.3389/fimmu.2024.1395427. eCollection 2024.
9
Vascular syk-ness: A new role for an old immunological favorite.血管中的 SYK：一个旧免疫学宠儿的新角色。
J Biol Chem. 2024 Jul;300(7):107517. doi: 10.1016/j.jbc.2024.107517. Epub 2024 Jun 28.
10
Development of a Time-Resolved Fluorescence Resonance Energy Transfer ultra-high throughput screening assay for targeting SYK and FCER1G interaction.用于靶向脾酪氨酸激酶（SYK）和高亲和力IgE受体γ链（FCER1G）相互作用的时间分辨荧光共振能量转移超高通量筛选分析方法的开发
bioRxiv. 2024 Jun 13:2024.06.11.598473. doi: 10.1101/2024.06.11.598473.
本文引用的文献
1
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.一种通过联合使用idelalisib和新型脾酪氨酸激酶（Syk）抑制剂GS-9973治疗慢性淋巴细胞白血病的潜在治疗策略。
Oncotarget. 2014 Feb 28;5(4):908-15. doi: 10.18632/oncotarget.1484.
2
SYK is a critical regulator of FLT3 in acute myeloid leukemia.SYK 是急性髓系白血病中 FLT3 的关键调节因子。
Cancer Cell. 2014 Feb 10;25(2):226-42. doi: 10.1016/j.ccr.2014.01.022.
3
SYK allelic loss and the role of Syk-regulated genes in breast cancer survival.SYK等位基因缺失以及Syk调控基因在乳腺癌生存中的作用。
PLoS One. 2014 Feb 11;9(2):e87610. doi: 10.1371/journal.pone.0087610. eCollection 2014.
4
B cell-specific loss of Lyn kinase leads to autoimmunity.B 细胞特异性 Lyn 激酶缺失导致自身免疫。
J Immunol. 2014 Feb 1;192(3):919-28. doi: 10.4049/jimmunol.1301979. Epub 2013 Dec 27.
5
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.新型口服生物可利用小分子抑制剂 RO9021 选择性抑制脾酪氨酸激酶 (SYK)，可影响各种固有和适应性免疫反应：SYK 抑制剂在自身免疫性疾病治疗中的应用。
Arthritis Res Ther. 2013 Oct 4;15(5):R146. doi: 10.1186/ar4329.
6
Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling.脾酪氨酸激酶（Syk）调节系统性红斑狼疮（SLE）T 细胞信号转导。
PLoS One. 2013 Aug 27;8(8):e74550. doi: 10.1371/journal.pone.0074550. eCollection 2013.
7
Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.炎症和免疫介导性疾病中开关激酶“脾酪氨酸激酶”抑制剂：综述。
Eur J Med Chem. 2013 Sep;67:434-46. doi: 10.1016/j.ejmech.2013.04.070. Epub 2013 Jul 12.
8
Toll-like receptor 4 mediates retinal ischemia/reperfusion injury through nuclear factor-κB and spleen tyrosine kinase activation.Toll 样受体 4 通过核因子-κB 和脾酪氨酸激酶的激活介导视网膜缺血/再灌注损伤。
Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5807-16. doi: 10.1167/iovs.13-11932.
9
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.深入了解 pre-BCR 和 BCR 信号转导与 B 细胞恶性肿瘤的关系。
Nat Rev Immunol. 2013 Aug;13(8):578-91. doi: 10.1038/nri3487.
10
Identification of direct tyrosine kinase substrates based on protein kinase assay-linked phosphoproteomics.基于蛋白激酶测定法相关磷酸化蛋白质组学鉴定直接酪氨酸激酶底物。
Mol Cell Proteomics. 2013 Oct;12(10):2969-80. doi: 10.1074/mcp.O113.027722. Epub 2013 Jun 22.
Zotero 插件